It looks like Shanghai Miracogen Inc.’s antibody-drug conjugate (ADC) partnership with Synaffix BV is paying off as MRG-004A, an ADC designed to treat solid tumors, has entered a U.S. phase I/II trial to treat solid tumors.
Little more than six months after filing a BLA for the antibody-drug conjugate (ADC) tisotumab vedotin in recurrent or metastatic cervical cancer, Seagen Inc. and Genmab A/S have secured an accelerated approval for the medicine. The green light for the co-developed product marks Seagen's third approved ADC and Genmab's first marketed therapy, though another medicine based on its Duobody technology platform recently won approval, too. The new cervical cancer drug, to be marketed as Tivdak, was approved for the treatment of adults experiencing disease progression on or after chemotherapy.
Monoclonal antibodies are already a pillar of cancer therapy, and cancer makes up the largest indication of FDA-approved antibodies, with almost 40% of the total. At the 2021 European Society of Medical Oncology (ESMO) Congress, Elena Garralda predicted that engineered versions of classical antibodies will soon join them on their pedestal.
Abclon Inc. has filled the missing link in its development of antibody-drug conjugates (ADCs) by partnering with Abtis Co. Ltd. and gaining access to its ADC linker.
Seagen Inc. and Remegen Co. Ltd. will collaborate to exclusively develop and commercialize disitamab vedotin, a humanized antibody-drug conjugate (ADC) targeting HER2, giving Remegen the chance to earn up to $2.4 billion in total milestone payments.
Astrazeneca plc and Daiichi Sankyo Co. Ltd. are pushing forward with a challenge to Roche Holding AG with breast cancer drug Enhertu (trastuzumab deruxtecan) after it demonstrated superiority over the Swiss firm’s Kadcyla (trastuzumab emtansine) in a head-to-head trial.
Seagen Inc. and Remegen Co. Ltd. will collaborate to exclusively develop and commercialize disitamab vedotin, a humanized antibody-drug conjugate (ADC) targeting HER2, giving Remegen the chance to earn up to $2.4 billion in total milestone payments.
Remegen Ltd.’s HER2-targeted disitamab vedotin became the first domestic antibody-drug conjugate (ADC) to win marketing approval in China, just three months after the company scored its first NDA approval in China for its lupus drug Tai’ai (telitacicept).
Byondis BV is gearing up for a U.S. filing of an antibody-drug conjugate (ADCs) in advanced HER2-positive breast cancer, but CEO Marco Timmers has grand plans to partner up with big pharma and expand into other diseases.
Cross-border startup Adcentrx Therapeutics Inc., with operations in San Diego and soon in Shanghai, secured $50 million in a series A financing round led by CBC Group to establish its presence in the antibody-drug conjugate (ADC) space.
